Keyphrases
Anti-PD-1 Monoclonal Antibody
50%
Anti-tumor Response
25%
Antitumor Efficacy
25%
Atezolizumab
50%
Avelumab
25%
Bladder Cancer
25%
Checkpoint Inhibitors
25%
Chemotherapeutic Regimens
25%
Chemotherapy Strategies
25%
Cisplatin
25%
Clinical Data
25%
Clinical Outcomes
25%
Combination Chemotherapy
25%
Durvalumab
25%
Enhanced Antitumor Efficacy
25%
Immune Checkpoint Blockade
100%
Immune Checkpoint Blockers
25%
Immune Therapy
25%
Ipilimumab
25%
Long-term Survival
50%
MEDLINE
25%
Metastatic Urothelial Carcinoma
25%
Monotherapy
25%
Muscle-invasive Bladder Cancer
75%
Neoadjuvant
100%
Neoadjuvant Immunotherapy
100%
Neoadjuvant Setting
50%
Neoadjuvant Therapy
25%
Nivolumab
25%
Pathological Complete Response
50%
Pembrolizumab
50%
Phase II Trial
75%
Planned Surgery
25%
Pre-surgical
50%
Prospective Clinical Trial
25%
Publicly Available
25%
Radical Cystectomy
100%
Response Rate
25%
Search Strategy
25%
Survival Benefit
25%
Systematic Literature Review
25%
Treatment Strategy
25%
Tremelimumab
25%
Upper Tract Urothelial Carcinoma
100%
Urothelial Carcinoma
25%
Medicine and Dentistry
Atezolizumab
50%
Avelumab
25%
Bladder
100%
Bladder Cancer
25%
Cisplatin
25%
Clinical Trial
25%
Combination Chemotherapy
25%
Cystectomy
100%
Durvalumab
25%
Immune Checkpoint Blockade
100%
Immunity
25%
Immunotherapy
100%
Ipilimumab
25%
Long Term Survival
50%
Monoclonal Antibody
50%
Monotherapy
25%
Muscle Invasive Bladder Cancer
75%
Neoadjuvant Therapy
25%
Nivolumab
25%
Pembrolizumab
50%
Phase II Trials
25%
Programmed Death-Ligand 1
25%
Systematic Review
25%
Ticilimumab
25%
Transitional Cell Carcinoma
100%
Pharmacology, Toxicology and Pharmaceutical Science
Atezolizumab
50%
Avelumab
25%
Bladder Cancer
25%
Chemotherapy
25%
Cisplatin
25%
Clinical Trial
25%
Durvalumab
25%
Immunotherapy
100%
Ipilimumab
25%
Long Term Survival
50%
Monoclonal Antibody
50%
Monotherapy
25%
Muscle Invasive Bladder Cancer
75%
Nivolumab
25%
Pembrolizumab
50%
Phase II Trials
25%
Transitional Cell Carcinoma
100%
Tremelimumab
25%